Page 53 - Read Online

119. Meng F, Henson R, Lang M, Wehbe H, Maheshwari S, Frazier ML, Killary AM, Sen S. MicroRNAs in plasma
Mendell JT, Jiang J, Schmittgen TD, Patel T. Involvement of of pancreatic ductal adenocarcinoma patients as novel
human micro-RNA in growth and response to chemotherapy blood-based biomarkers of disease. Cancer Prev Res (Phila)
in human cholangiocarcinoma cell lines. Gastroenterology 2009;2:807-13.
2006;130:2113-29. 134. Li A, Yu J, Kim H, Wolfgang CL, Canto MI, Hruban RH,
120. Kawahigashi Y, Mishima T, Mizuguchi Y, Arima Y, Goggins M. Serum miR-1290 as a marker of pancreatic
Yokomuro S, Kanda T, Ishibashi O, Yoshida H, cancer-response. Clin Cancer Res 2013;19:5252-3.
Tajiri T, Takizawa T. MicroRNA profi ling of human 135. Kawaguchi T, Komatsu S, Ichikawa D, Morimura R,
intrahepatic cholangiocarcinoma cell lines reveals biliary Tsujiura M, Konishi H, Takeshita H, Nagata H, Arita T,
epithelial cell-specifi c microRNAs. J Nippon Med Sch Hirajima S, Shiozaki A, Ikoma H, Okamoto K, Ochiai T,
2009;76:188-97. Taniguchi H, Otsuji E. Clinical impact of circulating miR-221
121. Chen X, Chen J, Liu X, Guo Z, Sun X, Zhang J. The in plasma of patients with pancreatic cancer. Br J Cancer
real-time dynamic monitoring of microRNA function in 2013;108:361-9.
cholangiocarcinoma. PLoS One 2014;9:e99431. 136. Caponi S, Funel N, Frampton AE, Mosca F, Santarpia L, Van
122. Karakatsanis A, Papaconstantinou I, Gazouli M, der Velde AG, Jiao LR, De Lio N, Falcone A, Kazemier G,
Lyberopoulou A, Polymeneas G, Voros D. Expression Meijer GA, Verheul HM, Vasile E, Peters GJ, Boggi U,
of microRNAs, miR-21, miR-31, miR-122, miR-145, Giovannetti E. The good, the bad and the ugly: a tale of
miR-146a, miR-200c, miR-221, miR-222, and miR-223 miR-101, miR-21 and miR-155 in pancreatic intraductal
in patients with hepatocellular carcinoma or intrahepatic papillary mucinous neoplasms. Ann Oncol 2013;24:734-41.
cholangiocarcinoma and its prognostic signifi cance. Mol 137. Lubezky N, Loewenstein S, Ben-Haim M, Brazowski E,
Carcinog 2013;52:297-303. Marmor S, Pasmanik-Chor M, Oron-Karni V, Rechavi G,
123. McNally ME, Collins A, Wojcik SE, Liu J, Henry JC, Jiang J, Klausner JM, Lahat G. MicroRNA expression signatures in
Schmittgen T, Bloomston M. Concomitant dysregulation intraductal papillary mucinous neoplasm of the pancreas.
of microRNAs miR-151-3p and miR-126 correlates Surgery 2013;153:663-72.
with improved survival in resected cholangiocarcinoma. 138. Farrell JJ, Toste P, Wu N, Li L, Wong J, Malkhassian D,
HPB (Oxford) 2013;15:260-4. Tran LM, Wu X, Li X, Dawson D, Wu H, Donahue TR.
124. Okamoto K, Miyoshi K, Murawaki Y. miR-29b, miR-205 and Endoscopically acquired pancreatic cyst fl uid microRNA
miR-221 enhance chemosensitivity to gemcitabine in HuH28 21 and 221 are associated with invasive cancer. Am J
human cholangiocarcinoma cells. PLoS One 2013;8:e77623. Gastroenterol 2013;108:1352-9.
125. Kaur S, Kumar S, Momi N, Sasson AR, Batra SK. Mucins 139. Dillhoff M, Liu J, Frankel W, Croce C, Bloomston M.
in pancreatic cancer and its microenvironment. Nat Rev MicroRNA-21 is overexpressed in pancreatic cancer
Gastroenterol Hepatol 2013;10:607-20. and a potential predictor of survival. J Gastrointest Surg
126. Camacho D, Reichenbach D, Duerr GD, Venema TL, 2008;12:2171-6.
Sweeney JF, Fisher WE. Value of laparoscopy in the staging 140. Jamieson NB, Morran DC, Morton JP, Ali A, Dickson EJ,
of pancreatic cancer. JOP 2005;6:552-61. Carter CR, Sansom OJ, Evans TR, McKay CJ, Oien KA.
127. Burris HA 3rd, Moore MJ, Andersen J, Green MR, MicroRNA molecular profi les associated with diagnosis,
Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, clinicopathologic criteria, and overall survival in patients with
Storniolo AM, Tarassoff P, Nelson R, Dorr FA, Stephens CD, resectable pancreatic ductal adenocarcinoma. Clin Cancer Res
Von Hoff DD. Improvements in survival and clinical benefi t 2012;18:534-45.
with gemcitabine as fi rst-line therapy for patients with 141. Frampton AE, Castellano L, Colombo T, Giovannetti E, Krell J,
advanced pancreas cancer: A randomized trial. J Clin Oncol Jacob J, Pellegrino L, Roca-Alonso L, Funel N, Gall TM,
1997;15:2403-13. De Giorgio A, Pinho FG, Fulci V, Britton DJ, Ahmad R,
128. Cardenes HR, Moore AM, Johnson CS, Yu M, Helft P, Habib NA, Coombes RC, Harding V, Knosel T, Stebbing J,
Chiorean EG, Vinson J, Howard TJ, Stephens AW, Tai DF, Jiao LR. MicroRNAs cooperatively inhibit a network of tumor
Loehrer PJ Sr. A phase II study of gemcitabine in combination suppressor genes to promote pancreatic tumor growth and
with radiation therapy in patients with localized, unresectable, progression. Gastroenterology 2014;146:268-77.e18.
pancreatic cancer: A Hoosier Oncology Group study. Am J 142. Yu J, Ohuchida K, Mizumoto K, Sato N, Kayashima T,
Clin Oncol 2011;34:460-5. Fujita H, Nakata K, Tanaka M. MicroRNA, hsa-miR-200c, is
129. Tang YT, Xu XH, Yang XD, Hao J, Cao H, Zhu W, an independent prognostic factor in pancreatic cancer and its
Zhang SY, Cao JP. Role of non-coding RNAs in pancreatic upregulation inhibits pancreatic cancer invasion but increases
cancer: the bane of the microworld. World J Gastroenterol cell proliferation. Mol Cancer 2010;9:169.
2014;20:9405-17. 143. Radhakrishnan P, Mohr AM, Grandgenett PM, Steele MM,
130. Sun T, Kong X, Du Y, Li Z. Aberrant microRNAs in pancreatic Batra SK, Hollingsworth MA. MicroRNA-200c modulates
cancer: Researches and clinical implications. Gastroenterol the expression of MUC4 and MUC16 by directly targeting
Res Pract 2014;2014:386561. their coding sequences in human pancreatic cancer. PLoS One
131. Halkova T, Cuperkova R, Minarik M, Benesova L. MicroRNAs 2013;8:e73356.
in pancreatic cancer: involvement in carcinogenesis and 144. Greither T, Grochola LF, Udelnow A, Lautenschlager C,
potential use for diagnosis and prognosis. Gastroenterol Res Wurl P, Taubert H. Elevated expression of microRNAs 155,
Pract 2015;2015:892903. 203, 210 and 222 in pancreatic tumors is associated with
132. Kong X, Du Y, Wang G, Gao J, Gong Y, Li L, Zhang Z, Zhu J, poorer survival. Int J Cancer 2010;126:73-80.
Jing Q, Qin Y, Li Z. Detection of differentially expressed 145. Bloomston M, Frankel WL, Petrocca F, Volinia S, Alder H,
microRNAs in serum of pancreatic ductal adenocarcinoma Hagan JP, Liu CG, Bhatt D, Taccioli C, Croce CM. MicroRNA
patients: miR-196a could be a potential marker for poor expression patterns to differentiate pancreatic adenocarcinoma
prognosis. Dig Dis Sci 2011;56:602-9. from normal pancreas and chronic pancreatitis. JAMA
133. Wang J, Chen J, Chang P, LeBlanc A, Li D, Abbruzzesse JL, 2007;297:1901-8.

154 Journal of Cancer Metastasis and Treatment ¦ Volume 1 ¦ Issue 3 ¦ October 15, 2015 ¦